NSP vs MAZE
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
NSP · Insperity$49.82 ▼ 1.97%
MAZE · Maze Therapeutics$34.19 ▲ 5.10%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- NSP +63.5%
- MAZE +12.1%
Head to head
| Metric | NSP | MAZE |
|---|---|---|
| Price | $49.82 | $34.19 |
| Change today | ▼ 1.97% | ▲ 5.10% |
| Market cap | $1.90B | $1.90B |
| Return, 3 months | -1.6% | +25.3% |
| Return, year to date | +36.3% | -17.5% |
| Return, 1 year | +58.5% | +19.5% |
| P/E (TTM) | 711.7 | – |
| P/B | 43.1 | 4.2 |
| P/E percentile vs own 5y | 100th | 42nd |
| Dividend yield | 4.82% | – |
| Revenue growth (YoY, latest qtr) | +1.7% | – |
| Net profit growth (YoY) | +95.0% | -32.8% |
| Gross margin | 13.0% | – |
| Operating margin | 0.3% | -728.1% |
| Net margin | 0.0% | -668.0% |
| Return on equity | 4.6% | -37.3% |
| Analyst target vs. price | -0.6% | +84.6% |
| Analyst buy share | 50% | 100% |
| RSI (14) | 49 | 67 |
| 30-day volatility | 63.2% | 51.5% |
| Max drawdown, 1 year | -56.7% | -56.8% |
| Trend read | Leaning bearish | Strong uptrend |
| Analyst consensus | Hold | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- MAZE is the largest of the group by market value.
- NSP has returned the most over the past year.
- NSP keeps the most profit per dollar of sales.
- MAZE has been the calmest stock over the last 30 days.